(Q36899259)

17 August 2017

1 reference

title

Acute viscerotropic disease following vaccination against yellow fever (English)

1 reference

17 August 2017

0 references

Edward B Hayes

1

1 reference

17 August 2017

31 July 2007

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

17 August 2017

1 reference

17 August 2017

101

1 reference

17 August 2017

10

1 reference

17 August 2017

967-971

1 reference

Effects of yellow fever vaccination

17 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

History of thymoma and yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Rare case of fatal yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Anaphylaxis from yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Restricted replication and lysosomal trafficking of yellow fever 17D vaccine virus in human dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Positional cloning of the murine flavivirus resistance gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

New developments in flavivirus vaccines with special attention to yellow fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Understanding the role of innate immunity in the mechanism of action of the live attenuated Yellow Fever Vaccine 17D.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Yellow fever virus isolated from a fatal post vaccination event: an experimental comparative study with the 17DD vaccine strain in the Syrian hamster (Mesocricetus auratus).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

RNase L plays a role in the antiviral response to West Nile virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Risk of fatal adverse events associated with 17DD yellow fever vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Yellow fever vaccine is safe and effective in HIV-infected patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Effects of yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

Genetic divergence and dispersal of yellow fever virus, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRSTMH.2007.06.013

10.1016/J.TRSTMH.2007.06.013

7 January 2021

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17669451